Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

Idorsia's daridorexant gains FDA breakthrough therapy designation for pediatric insomnia

By Public Technologies
  • Idorsia received FDA Breakthrough Therapy Designation for daridorexant to treat insomnia in patients aged 10 to under 18.
  • Reported Phase 2 results showed improved total sleep time, with pronounced benefits in patients with neurodevelopmental disorders and favorable tolerability.
  • The full study manuscript is under journal review; the Phase 3 program is expected to begin in the second half of 2027.
  • The designation enables intensive FDA guidance to accelerate development and review in a market with no FDA-approved pediatric insomnia drugs.
  • Daridorexant remains investigational for pediatric use, with no marketing authorization for children or adolescents in any country.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Idorsia Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040100PRIMZONEFULLFEED1001301632) on November 04, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.